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Abstract: Background:
Paediatric ulcerative colitis (UC) presents at an earlier age and increasing prevalence.
Our aim was to examine morbidity, steroid sparing strategies, and surgical outcome in
children with active UC.
Methods:
A national prospective audit was conducted for the inpatient period of all children with
ulcerative colitis for medical or surgical treatment in the UK over one year. 32
participating centres recruited 224 children in 298 admissions, comparisons over 6
years were made with previous audits.
Results:
Over six years, recording of PUCAI score (median 65)(23% to 55%, p<0.001),
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guidelines for acute severe colitis (43% to 77%, p 0.04), and ileal pouch surgery
registration (4% to 56%, p<0.001) have increased.
Corticosteroids were given in 183/298 episodes (61%) with 61/183 (33%) not
responding and requiring second line therapy or surgery. Of those treated with anti-
TNFalpha (16/61, 26%), 3/16 (18.8%) failed to respond and required colectomy.
Prescription of rescue therapy (26% to 49%, p=0.04) and proportion of anti-TNFalpha
(20% to 53%, p=0.03) had increased, colectomy rate (23.7% to 15%) was not
significantly reduced (p=0.5).
Subtotal colectomy was the most common surgery performed (n=40), and surgical
complications from all procedures occurred in 33%. In 215/224 (96%) iron deficiency
anaemia was detected and in 51% treated, orally (50.2%) or intravenously (49.8%).
Conclusions:
A third of children were not responsive to steroids, and a quarter of these were treated
with anti-TNFalpha. Colectomy was required in 41/298 (13.7%) of all admissions. Our
national audit programme indicates effectiveness of actions taken to reduce steroid
dependency, surgery, and iron deficiency.
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September 25, 2017 
 
To the Editors of Inflammatory Bowel Diseases, 
Bret A. Lashner, M.D., M.P.H. 
Professor of Medicine 
Center for Inflammatory Bowel Disease 
Department of Gastroenterology 
Digestive Disease Institute 
Cleveland Clinic 
Cleveland, Ohio 
 
 
Fabio Cominelli, M.D., Ph.D. 
Professor of Medicine and Pathology 
Associate Dean for Program Development 
Chief, Division of Gastroenterology & Liver Disease 
Hermann Menges, Jr. Chair in Internal Medicine 
Director, Digestive Health Research Institute 
Director, NIH Cleveland Digestive Diseases Research Core Center 
Case Western Reserve University 
Chief Scientific Officer, Digestive Health Institute 
University Hospitals Cleveland Medical Center 
Cleveland, Ohio 
 
Dear Professor Lashner, 
Dear Professor Cominelli, 
 
Re: IBD-D-17-00570 entitled “Improved medical treatment and surgical surveillance 
of children and adolescents with ulcerative colitis in the United Kingdom" 
 
We are delighted that you find our paper acceptable to publication in Inflammatory 
Bowel Diseases pending appropriate revision to address your reviewers' comments. 
 
In response to the helpful and constructive suggestions from the three reviewers, we 
have specifically addressed all issues in our structured response and hereby submit 
our revised manuscript.  
Response to Reviewers, formatted
We believe that the amendments in response to the reviewers’ comments have 
further improved the quality of our paper.  
 
We are looking very much forward to your decision, 
 
With kind regards, 
 
Yours sincerely 
 
 
 
Marcus KH Auth, M.D., P.D.  
Consultant Paediatric Gastroenterologist 
 
  
Reviewer #1:  
 
Dear reviewer, 
Thank you very much for your helpful and constructive comments, which we have all 
addressed in itemised form below and in our specifically revised manuscript: 
 
 
1.  The expression "Young UC patients" is extremely ambiguous. The absence of age 
restriction affects the analysis result. At least the age distribution of the patients should be 
demonstrated. Especially, the information of very early onset UC patient is important. Is the 
percentage of them changing in survey of each era? In very early onset UC patients, are 
there features in treatment contents and surgery rates compared with other pediatric UC 
patients? 
 
 
We have added the fully available biometric data including age distribution (median 
with IQR) and gender to Materials and Methods. We fully agree with the reviewer 
that the information of very early onset UC patients is important, and have added the 
biometric data to this audit. Unfortunately we had no access to the full biometric data 
from the previous audit rounds to elucidate if the percentage has changed over the 
years, or to investigate difference on medical and surgical treatment of children 
initially presenting with VEOIBD or later onset IBD in this audit. 
We hope that the reviewer agrees that we have not discussed this issue formally in 
the discussion as we are not presenting the data in this manuscript.  
 
Materials and Methods:  
32 sites in the UK (total UK population 64.1 million in 2013, Office for national Statistics) 
entered clinical data on up to 50 consecutive admissions of children between less than 3 
and up to 18 years between 1 January and 31 December 2013. 
 
Table 1: 
Patient demographics and characteristics 
  Median (IQR) 
% (numerical) 
Age Total n=224 children 14 (11, 15) years 
Age distribution < 3  0.9% (2/224) 
 < 6 years 3.6% (8/224) 
 6 -18 years 95.5% (214/224) 
 
2.  In Table1, ileal pouch surgery entered on registry significantly increased in round 4. 
Is this due to an increase in facilities with UC surgeon or due to the increasing number of 
pediatric UC patients with surgical indications? Does the actual surgical rate in pediatric UC 
in UK increase compared to the past? Does increase of anti-TNF use affect colectomy rate? 
 
 
The number of ileal pouch surgery performed (n=16) was not higher than on the 
previous audit (n=23), however patient’s details were collected on a national surgical 
database (1/23, 4.3% of n=23 in round 3; versus 9/16, 56% of n-16 in round 4).   
To answer the first part of the questions, our surgical colleagues have previously 
conducted national and regional surveys among all UK paediatric surgeons with a 
sub-specialist interest in IBD: 
Smith NP, Ba'ath ME, Perry D, Morgan LE, Lamont GL, Baillie CT. BAPS UK 
inflammatory bowel disease surgical practice survey. J Pediatr Surg. 2007 
Feb;42(2):296-9. 
 
“Annual consultant caseload was requested for colonoscopy, J-pouch ileoanal 
anastomosis (IPAA) for ulcerative colitis, and strictureplasty (Crohn's disease). The 
median experience with IPAA was 0.9 cases per year of consultant practice (range, 
0-3.7), and 12.5% of surgeons had limited experience of revision pouch surgery. The 
majority have arrangements for joint operating with adult surgeons for IPAA. 
Experience with IPAA is limited for most surgeons. Whether children should undergo 
elective IPAA independent of experienced adult practitioners, who naturally assume 
responsibility after transition, requires careful debate.” 
 
As we have not collected follow-up data in this audit, it is possible that more patients may 
undergo ileal pouch surgery after transition to the adult units, keeping in mind that in this 
audit 90% of units were found to have transitional care in place (Table 1). Because we have 
been asked by all reviewers to condense the discussion in our manuscript, we have not 
quoted this data, but provided a short explanation in the results section and discussion: 
 
For the first time in this audit, all medical and surgical admissions were captured for this IBD 
cohort over a year, and surgical data such as ileal pouch surgery were captured 
systematically to monitor both frequency (table 3) and outcome (tables 4+5). 
 
Because participating centres had been asked in previous audits to enter up to 20 
consecutive medical and surgical admissions per centre, we are unable to elucidate if the 
overall surgical rate in paediatric UC has increased over the years.  
We thank the reviewer for the important question if the use of anti-TNFalpha reduces the 
colectomy rate. We have now provided the number of colectomies for steroid failure and 
compared these to the previous audits. A slight reduction of the colectomy rate versus the 
first audit round was not significant. On the contrary, the numbers of patients who received 
anti-TNFalpha for rescue therapy has increased significantly for rescue therapy (20% to 
53%, p=0.03 from 2008/2010 to 2012/2014) and for maintenance from 5% to 14% (p=0.02) 
from 2010-2012. 
 
Because of the relevance of the finding, we have added a statement in the abstract, results 
section and discussion, and have added colectomy rates and p-values under proportion of 
TNF-alpha usage in table 3:  
 
Abstract:  
Prescription of rescue therapy (26% to 49%, p=0.04) and proportion of anti-TNFalpha (20% 
to 53%, p=0.03) had increased, colectomy rate (23.7% to 15%) was not significantly reduced 
(p=0.5). 
 
Results: 
A comparison of this audit documenting improvements to the previous 2 national audit 
rounds is shown in table 3 highlighting significant increases in guideline use, PUCAI 
recording, Clostridium difficile (C. difficile) analysis, anti-TNFalpha use, and colectomy rate.  
… 
Comparison of the audits rounds illustrates an increasing number of patients receiving anti-
TNFalpha for rescue and maintenance therapy, but a similar proportion of children with UC 
requiring colectomy (table 3). 
 
Table3:  
 
 
Discussion: 
Along with an increasing number of patients treated with anti-TNFalpha, fewer children 
required colectomy, although this did not reach statistical significance. For future studies, it 
would be valuable to examine how patients perceived the preparation and timing of 
colectomy with regard to their quality of life, impact on growth, puberty, and psychosocial 
development. 
 
 
3.  In Figure 4, thiopurine was used as a steroid sparing management (28/45). Condition 
of EBV infection should be concerned when we use thiopurine in pediatric patients. EBV titer 
was examined? How many centres did check EBV infection status prior to thiopurine use? 
 
 
We agree with a reviewer on that point and since the audit was conducted, we and 
many other paediatric centres included EBV titer/EBV infection status routinely into 
our IBD protocol for new and existing patients. For this audit, no information had 
been collected how many centres assessed the EBV status before commencing 
thiopurines. We have forwarded this topic to the national IBD working group to 
address this formally in future audits and guidelines.  
 
 
4. Discussion part is too long. The authors should focus more and discuss them 
compactly. 
 
 
We agree with the reviewer and have condensed the discussion substantially from 9 
to 6 pages. We have focussed on the most important findings in relation to what has 
been previously shown and have concluded our main findings at the end. 
  
Variables examined Round 2 
2008-10 
Round 3 
2010-12 
Round 4 
2012-14 
χ2 test, p-value 
Plans for maintenance anti-TNFalpha Not asked 5% (11/173) 14% (24/177) 0.02 
Colectomy rate in steroid failures  23.7% (9/38) 15.2% (5/33) 15% (9/61) 0.50 
Reviewer #2:  
 
 
Dear reviewer, 
Thank you very much for your helpful and constructive comments, which we have all 
addressed in itemised form below and in our specifically revised manuscript: 
 
 
The strengths of this study is that it is a detailed description of over 200 admissions 
for ASUC in children and provides reasonably contemporary outcome data. Weakness 
include the lack of clarity whether data at the sites were collected retrospectively, description 
of outcomes from over 3 years ago, and lack of focus in the discussion. 
 
 
We thank the reviewer for the valuable comment and suggestions. Data were 
collected in the year of the audit in the individual centres with a deadline set for data 
entries for each patient. Analysis was then conducted by the Royal College of 
Physicians (RCPCH) and a generic report was prepared by the national audit leads 
with additional columns for each participating centre. The authors of this manuscript 
then compared results of this audit with previous audits and retrieved further raw 
data from the original dataset, once they had support from a designated statistician. 
Because of the substantial work involved, this process was divided between the first 
authors (MA and SB) and the audit team, and involved a critical and constructive 
reviewing process from the many centres and experts involved.  
While we share the view that it is preferable to publish data as soon as possible, we 
believe that the strength of our paper, i.e. representative participation from 32 
centres with 298 paediatric admissions, outweighs the delay mentioned.  
 
 
Specific Comments: 
1. Patient characteristics are described in page 8 starting line 9, but there should be a 
detailed "Table 1" with the characteristics of the patients (age, gender, Paris classification, 
medications at admission, time since diagnosis, etc) 
 
 
We fully agree and consequently have generated a detailed Table 1 with those 
characteristics: 
 
Table 1: 
Patient demongraphics and characteristics 
 
  Median (IQR) 
% (numerical) 
Age Total n=224 children 14 (11, 15) years 
Age distribution < 3  0.9% (2/224) 
 < 6 years 3.6% (8/224) 
 6 -18 years 95.5% (214/224) 
Gender Female 50.4% (113/224) Male 49.6% (111/224) 
 
Paris classification Proctitis (E1) 3% (8/298) 
 Left sided (E2) 18% (54/298) 
 Extensive (E3) 17% (52/298) 
 Pan colitis (E4) 51% (151/298) 
 Unknown 11% (33/298) 
Medication of patients not 
admitted from clinic 
5-ASA 52% (53/103)  
 Steroids 52% (53/103) 
 Topical 52% (53/103) 
 Thiopurine 52% (53/103) 
Ambulatory disease 
management 
Days prior to admission 26 (7, 61) days 
Previous admissions  Admitted for UC in previous 2 
years 
41% (92/212)  
PUCAI  On admission 60 (50, 70) 
 On discharge 15 (7.5,  25) 
Length of stay  6 (3, 10) days 
Type of admission  Newly diagnosed severe UC 18% (55/298)  
 Emergency admissions for 
established UC 
44% (131/298) 
 Elective medical or surgical 
admissions for known UC 
27% (52/298) 
 Transfer from other sites 11% (36/298) 
Comorbidity None 82% (245/298) 
 Cardiovascular 0.3% (1/298) 
 Respiratory 4% (11/298) 
 Diabetes 1% (4/298) 
 IBD related liver disease 7% (20/298) 
 Active cancer 0.7% (2/298) 
 Other 6% (17/298) 
Admissions n=298 admissions 13 (11, 14) years) 
 
 
2. It appears a major conclusion is that by conducting these audits, sites improve in 
quality improvement measures and while these measures are detailed in Table 1, there is 
little mention of the measures specifically in the results (more on patient characteristics and 
treatment).  
 
 
Quality improvement measures have been applied to outpatient and inpatient 
management of these patients, and different audit rounds have focussed on different 
aspects of the overall management, e.g. provision of specialist nurses and dieticians 
with telephone and clinic access. As markers for quality improvement, in this paper 
we have presented results for steroid dependency, treatment of iron deficiency 
anaemia, and colectomy rate. Other quality measures from the full audit report (ref. 
17), such as proportion of bone protection prescribed (addressed for the first time in 
this audit round), were not presented here to keep the focus and manuscript length 
concise. 
Following the reviewer’s advice, we have the following paragraphs about quality 
improvement.  
 
As explained in question 1, we have added a new table (new table 1), which 
summarises measures taken, e.g. recognition of disease activity by applying PUCAI 
scores, attempts to reduce waiting time from symptom presentation to treatment by 
availability of specialist nurse, reduction of steroid side effects by prescription of 
second-line treatments, etc. We have added colectomy rate into the amended new 
table 3, and have discussed the effect of these measures taken: 
 
Table 1: 
Patient demographics and characteristics 
(please refer to table above in question 1) 
 
Results: 
Comparison to previous audits 
A comparison of this audit documenting improvements to the previous 2 national audit 
rounds is shown in table 3 highlighting significant increases in guideline use, PUCAI recording, 
Clostridium difficile (C. difficile) analysis, anti-TNFalpha use, and colectomy rate.  
 
Quality improvement 
The national and local efforts to improve service provision by implementing action plans from 
previous audits is reflected in table 3, indicating increase of clinical nurse specialists, 
establishment of guidelines for ASC, recording of PUCAI score, transitional care plans, and 
other (table 3). The high proportion of patients seen within 7 days reflects improvements in 
surveillance and efficacy of specialist service response for children with UC.  
 
Table 3: 
Comparison of the paediatric data in 3 rounds of the national UK inflammatory bowel disease 
(IBD) audits 
Variables examined Round 2 
2008-10 
Round 3 
2010-12 
Round 4 
2012-14 
χ2 test, p-value 
 
Relapsing patients seen within 7 days 87% (20/23) 91% (21/23) 94% (29/31) 0.71 
 
Colectomy rate in steroid failures  23.7% (9/38) 15.2% (5/33) 15% (9/61) 0.50 
 
 
Some of the measure in table 1 are difficult to understand including "Relapsing 
patient seen within 7 days" (7 days from when, when are they assessed to be relapsing - 
and also this is not a patient specific metric) - in general the quality indicators should be 
better defined.  
 
 
The quality indicators from Table 1 were chosen by national adult and paediatric leads, 
sometimes as part of overarching national quality improvement programs e.g. for waiting 
times or transition arrangments, and published in national IBD standards. As suggested by 
the reviewer, we have provided an explanation for measures presented in table 1 (now 
table3) and the reference link to the national IBD standards:  
 
Results: 
Quality improvement 
Based on agreed national IBD standards, the concept for service improvements was to 
implement local actions identified as problems in previous audits (7). This is illustrated in 
table 3, indicating increase of clinical nurse specialists (who provide direct and continuous 
contact and advice), establishment of guidelines for ASC (to reduce treatment variability and 
provide adherence to evidence-based protocols), recording of PUCAI score (to reduce bias in 
assessment of disease activity and treatment), transitional care plans (to facilitate continuity 
of specialist care), and other (table 3) (7). It had been recognised in previous audits that GPs 
in the UK were unfamiliar in the management of children with IBD, therefore the high 
proportion of patients seen within 7 days reflects improvements in surveillance and efficacy 
of a more rapid specialist service response for children with UC.  
 
 
3. The discussion is simply too long and diffuse at 9 pages. Should really be 4-6 pages. 
There is a lot of data in this paper but the authors would better serve the reader by 
narrowing down on what they feel the most important findings are, how it fits with what has 
previously been shown, and conclude with the main conclusions. 
 
 
We agree with the reviewer and have condensed the discussion substantially from 9 
to 6 pages. We have focussed on the most important findings in relation to what has 
been previously shown and have concluded our main findings at the end. 
 
 
 
  
Reviewer #3:  
 
 
Dear reviewer, 
Thank you very much for your helpful and constructive comments, which we have all 
addressed in itemised form below and in our specifically revised manuscript: 
 
 
Anyhow, the results and discussion sections are not well balanced; in fact, the result 
section is quite short, even though crowded with data, giving lots of interesting information 
that may, however, be difficult to be the fully extrapolated from the text by the readers. I 
would suggest expanding this section, in order to "dilute" the data for easier reading. On the 
contrary, the discussion is very long and should be shortened. 
 
 
We agree with the reviewer that some of the results data could be better illustrated. 
Accordingly, to dilute some of the data for the readers, we have added table 1 which 
illustrates patient demographics and some of the text section of the results from this 
audit.  
In further response, we have condensed the discussion substantially from 9 to 6 
pages. We have focussed on the most important findings in relation to what has 
been previously shown and have concluded our main findings at the end. 
 
 
 
Table 1: 
Patient demographics and characteristics 
 
  Median (IQR) 
% (numerical) 
Age Total n=224 children 14 (11, 15) years 
Age distribution < 3  0.9% (2/224) 
 < 6 years 3.6% (8/224) 
 6 -18 years 95.5% (214/224) 
Gender Female 50.4% (113/224) Male 49.6% (111/224) 
 
Paris classification Proctitis (E1) 3% (8/298) 
 Left sided (E2) 18% (54/298) 
 Extensive (E3) 17% (52/298) 
 Pan colitis (E4) 51% (151/298) 
 Unknown 11% (33/298) 
Medication of patients not 
admitted from clinic 
5-ASA 52% (53/103)  
 Steroids 52% (53/103) 
 Topical 52% (53/103) 
 Thiopurine 52% (53/103) 
Ambulatory disease 
management 
Days prior to admission 26 (7, 61) days 
Previous admissions  Admitted for UC in previous 2 
years 
41% (92/212)  
PUCAI  On admission 60 (50, 70) 
 On discharge 15 (7.5,  25) 
Length of stay  6 (3, 10) days 
Type of admission  Newly diagnosed severe UC 18% (55/298)  
 Emergency admissions for 
established UC 
44% (131/298) 
 Elective medical or surgical 
admissions for known UC 
27% (52/298) 
 Transfer from other sites 11% (36/298) 
Comorbidity None 82% (245/298) 
 Cardiovascular 0.3% (1/298) 
 Respiratory 4% (11/298) 
 Diabetes 1% (4/298) 
 IBD related liver disease 7% (20/298) 
 Active cancer 0.7% (2/298) 
 Other 6% (17/298) 
Admissions n=298 admissions 13 (11, 14) years) 
 
 
 
Another critical point is that two centers (Liverpool and Newcastle) enrolled almost 
half of patients (41%); indeed, this issue greatly reduces the statistical weight of those 
centers, which have contributed with smaller number of patients. It would be interesting to 
have a table showing the number of patients enrolled by each single center. In addition, it 
may be worthy to show whether or not there are discrepancies in caring strategies in the 
different centers, according to the center size. 
 
 
In response to the reviewer’s suggestions, we have added a table with number of 
patients enrolled by each single centre (table 2). 13 centres entered more, and 15 
centres more than the median. One purpose of the audit was to capture the real-life 
patient experience throughout the country, acknowledging existing variation in 
commissioning and service provision, to identify and address regional areas for 
development.  
As briefly outlined in the discussion, Liverpool and Newcastle had no discrepant 
caring strategies, apart from Liverpool (50/298 admissions) using high dose 
intravenous steroids as first line treatment in acute severe colitis, and their 
experiences have been published before (reference 22) and are briefly discussed.  
As explained in the results section, Newcastle and Liverpool had a larger IBD 
population and had medical care arrangements to admit patients from their 
population directly into their (tertiary) hospitals. We acknowledged that in table 2, 
results and discussion.  
 
Table 2: National recruitment of children with UC admitted over 1 year 
 
Centre City Admissions  
Alder Hey Children’s Hospital Liverpool 16.8% (50/298) 
Great North Children’s 
Hospital 
Newcastle upon Tyne 12.1% (36/298) 
Chelsea and Westminster 
Hospital, Children’s Services 
London 5.7% (17/298) 
Birmingham Children’s 
Hospital 
Birmingham 5.4% (16/298) 
Royal Hospital for Children 
Glasgow 
Glasgow 5.4% (16/298) 
Royal London Children’s 
Hospital, Barts Health 
London 5.0% (15/298) 
Southampton Children’s 
Hospital 
Southampton 4.7% (14/298) 
Leicester Royal Infirmary 
Children’s Hospital 
Leicester 4.0% (12/298) 
Royal Bristol Hospital for Sick 
Children 
Bristol 3.7% (11/298) 
King’s College Hospital London 3.7% (11/298) 
Children’s Hospital, John 
Radcliffe 
Oxford 3.4% (10/298) 
Leeds General Infirmary Leeds 2.7% (8/298) 
University Hospitals of 
North Midlands 
Stoke 2.7% (8/298) 
Royal Hospital for Sick Children 
Edinburgh 
Edinburgh 2.0% (6/298) 
Nottingham Children’s Hospital Nottingham 2.0% (6/298) 
Royal Free Hospital London 2.0% (6/298)  
Queen Mary’s Hospital for 
Children 
St Epsom and Helier 2.0% (6/298) 
St George’s Hospital London 2.0% (6/298) 
Morriston Hospital Swansea 1.7% (5/298) 
Addenbrooke’s Hospital Cambridge 1.7% (5/298) 
Tunbridge Wells Hospital Maidstone 1.7% (5/298) 
Royal Aberdeen Children’s 
Hospital 
Aberdeen 1.3% (4/298) 
Royal Belfast Hospital for Sick 
Children 
Belfast 1.3% (4/298) 
Royal Devon and Exeter 
Hospital 
Exeter 1.3% (4/298) 
Great Ormond Street Hospital London 1.3% (4/298) 
Luton and Dunstable University 
Hospital 
Luton 1% (3/298) 
Sheffield Children’s Hospital Sheffield 1% (3/298) 
Noah’s Ark Children’s Hospital Cardiff 0.7% (2/298) 
Jenny Lind Children’s Hospital Norwich 0.7% (2/298) 
University Hospital of North 
Tees 
Hartlepool 0.03% (1/298) 
The Children’s Hospital 
Lewisham 
Lewisham 0.03% (1/298) 
Royal Manchester Children’s 
Hospital 
Manchester 0.03% (1/298) 
Queen’s Hospital Burton Burton 0% (0/298) 
 
Results:  
The mode of admission (elective versus emergency) was higher electively in 
Liverpool/Newcastle (20/86, 23%) versus others (23/212, 11%)(p=0.004) and respectively 
Liverpool/Newcastle had a lower rate of emergency admissions (30/86, 35%) versus other 
centres (102/212, 48%) (p=0.037). A slightly higher rate of readmissions of children with UC 
in Liverpool/Newcastle in the previous two years (54/86, 63%) versus others (112/212, 53%) 
was statistically not significant (p=0.12), and if patients had to be admitted for surgery or 
had surgery performed their proportion was similar in Liverpool/Newcastle to  the other 
centres. 
Although not formally asked in the audit questionnaire, we further interviewed participating 
centres if there was a treatment difference regarding steroid application, steroid sparing, 
2nd line therapy, or use of biologics. In their region, children requiring inpatient treatment 
for UC were always admitted in Liverpool and Newcastle, while it was practice in some 
other tertiary centres to arrange admission and treatment for less severe UC in secondary 
hospitals from their network. In acute severe colitis (PUCAI score 65-85) , the Liverpool 
centre administered i.v. steroids as high dose bolus (20mg/kg), but applied similar second 
line treatment and steroid reduction scheme as other units.  
 
Discussion:  
Notably, an alternative treatment for successful treatment of ASC published recently by the 
Liverpool centre, was applied in 5% (15/298) of children admitted in this audit (22). Based 
on a short-term course of high dose (20mg/kg) iv methylprednisolone, with this protocol the 
steroid dependency rate had been reported before as 21% after 6 months and 0% after 1 
year (22).  
… 
In contrast to other published national reports, which were limited to tertiary centres (14, 
19,30), our audit was truly representative for the national practice including 9% of patients 
with severe UC managed in non-specialised sites. We observed a wide range in the 
catchment area, size of the IBD population, and referral pattern within regional networks 
over the audit period. The audit illustrated variation in areas of service provision (e.g. risk 
assessment by a nutritional screen) or compliance to quality standards (e.g. prescription of 
bone protection), which enables each individual hospital to benchmark against the national 
median and IQR (7, 17).  
 
 
Furthermore, we examined key indicators of care provisions in hospitals admitting 
between 6 (2%, 6/298) and 50 admissions, which comprised 85.2% (254/298) 
admissions. These included 7 variables: (i) Seen by a paediatric IBD nurse during 
admission in patients admitted as an emergency, (ii) Recording of PUCAI score on 
Day 1 of emergency admissions, (iii) Stool sample sent for standard stool culture 
(SSC), where the patient had diarrhoea, (iv) Stool sample sent for Clostridium 
difficile toxin (CDT), where the patient had diarrhoea, (v) Nutritional screen (risk 
assessment) undertaken during admission, (vi) Bone protection prescribed in those 
discharged home on steroids, (vii) Clear plan to follow up the patient that was 
recorded in the notes at discharge. This yielded a wide range of individual hospital’s 
fulfilment from 0% to 100%, which revealed gaps both in larger and smaller 
recruitment sites. Data from this audit did not suggest fundamental discrepancies 
between centres of different sites, but comparison of different rounds of audits 
suggested that participation in the audit contributed to improving delivery of 
nationally agreed protocols and standards.  
 
As hospitals with 0-5 admissions (14.8%, 44/298 from all admissions) had not been 
sub-analysed by the audit leads individually, unfortunately we are unable to calculate 
discrepancy of treatments according to centre size between all centres. 
 
 
Together with the results on anaemia, Authors may want to add, if possible, data on 
other extra-intestinal manifestations, about their distribution and therapies. 
 
 
We have added data on extra-intestinal manifestations in an additional table 1: 
 
Comorbidity None 82% (245/298) 
 Cardiovascular 0.3% (1/298) 
 Respiratory 4% (11/298) 
 Diabetes 1% (4/298) 
 IBD related liver disease 7% (20/298) 
 Active cancer 0.7% (2/298) 
 Other 6% (17/298) 
 
This was asked the first time in the national audit and unfortunately no further 
questions had been asked about distribution and therapies. However, our centre has 
addressed the issue of paediatric primary sclerosing cholangitis in a global multi-
centre paper published recently (Deneau MR, et al. The natural history of primary 
sclerosing cholangitis in 781 children: A multicenter, international collaboration. 
Hepatology. 2017 Aug;66(2):518-527. doi: 10.1002/hep.29204. Epub 2017 Jun 26.).  
 
 
3. The discussion is simply too long and diffuse at 9 pages. Should really be 4-6 pages. 
There is a lot of data in this paper but the authors would better serve the reader by 
narrowing down on what they feel the most important findings are, how it fits with what has 
previously been shown, and conclude with the main conclusions. 
 
 
We fully agree with the reviewer. Accordingly, we have condensed the discussion 
substantially from 9 to 6 pages and have rewritten some paragraphs e.g. for analysis 
of surgery or for geographical differences. We have focussed on the most important 
findings in relation to what has been previously shown and have concluded our main 
findings at the end: 
 
Conclusions:  
Over 6 years, progress has been made that nearly all centres providing secondary and 
tertiary gastroenterology contributed to the national audit rounds, applying agreed quality 
standards of PUCAI score, guidelines for acute severe colitis, and ileal pouch surgery 
registration. Nearly all children admitted had iron deficiency anaemia and half of them were 
prescribed oral or intravenous iron therapy, both considered as effective. More than half of 
inpatients with UC required iv steroids and of those one third were not responding and 
requiring second line therapy or surgery.  
More than half children with rescue therapy received anti-TNFalpha, and nearly 20% of 
those failed to respond and required colectomy. Although prescription of rescue therapy 
(50%) and proportion of anti-TNFalpha (50% of those) had significantly increased, over a 
period of 6 years the reduction of colectomy rate (15%) had not reached statistical 
significance. Subtotal colectomy was required in 13.7% of patients admitted, nearly half of 
them admitted non-electively, and complications occurred in one third of surgical patients 
with UC.  
Our national audit programme has proven effective to reduce steroid side-effects and iron 
deficiency anaemia in children with UC. Although over 6 years in the era of biologics there 
was a trend of decreasing colectomy rates, nearly half of children requiring colectomy had 
to be operated non-electively, indicating the importance of early recognition, optimising 
treatment, and collaborative gastro-surgical assessment. 
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Abstract 
 
 
Background: 
Paediatric ulcerative colitis (UC) presents at an earlier age and increasing prevalence. Our aim 
was to examine morbidity, steroid sparing strategies, and surgical outcome in children with 
active UC. 
 
Methods: 
A national prospective audit was conducted for the inpatient period of all children with 
ulcerative colitis for medical or surgical treatment in the UK over one year. 32 participating 
centres recruited 224 children in 298 admissions, comparisons over 6 years were made with 
previous audits.  
 
Results: 
Over six years, recording of PUCAI score (median 65)(23% to 55%, p<0.001), guidelines for 
acute severe colitis (43% to 77%, p 0.04), and ileal pouch surgery registration (4% to 56%, 
p<0.001) have increased. 
Corticosteroids were given in 183/298 episodes (61%) with 61/183 (33%) not responding and 
requiring second line therapy or surgery. Of those treated with anti-TNFalpha (16/61, 26%), 
3/16 (18.8%) failed to respond and required colectomy. Prescription of rescue therapy (26% to 
49%, p=0.04) and proportion of anti-TNFalpha (20% to 53%, p=0.03) had increased, 
colectomy rate (23.7% to 15%) was not significantly reduced (p=0.5).  
Main Document
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Subtotal colectomy was the most common surgery performed (n=40), and surgical 
complications from all procedures occurred in 33%. In 215/224 (96%) iron deficiency anaemia 
was detected and in 51% treated, orally (50.2%) or intravenously (49.8%).  
 
Conclusions: 
A third of children were not responsive to steroids, and a quarter of these were treated with 
anti-TNFalpha. Colectomy was required in 41/298 (13.7%) of all admissions. Our national 
audit programme indicates effectiveness of actions taken to reduce steroid dependency, 
surgery, and iron deficiency.  
 
 
 
 
 
 
Key words:  
 
Ulcerative colitis, anti-TNFalpha, colectomy, iron deficiency, steroid dependency. 
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Background: 
 
 
Ulcerative colitis (UC) developing in the paediatric age range tends to be more extensive and 
severe than seen in adult patients with higher colectomy rates (1). Recent advances in 
standardising (with the aim of improving) care of young people with UC include the 
development and validation of a simple clinical scoring system for disease activity, the 
Pediatric UC Activity Index (PUCAI) (2,3) together with publication of evidence based 
guidelines for the management of paediatric UC and acute severe ulcerative colitis (ASC) (4,5). 
UK national standards of care for adults, children and young people with UC have also been 
outlined by the National Institute for Health and Care Excellence (NICE) (6) and the UK IBD 
Standards (7). 
 
A modest increase in the incidence of paediatric UC has been reported (8-10). The disease 
adversely affects quality of life (11,12) and the three-month, per-patient cost for UC was 
calculated at £1211 in 2010 (13), with the majority of this cost attributed to inpatient stays. It 
is therefore important both on a patient level and national level to understand details of inpatient 
care required by children and young people with UC.  
Majority of inpatient care of young people with UC is for the management of ASC, a potentially 
life threatening condition. Approximately 70% of children with ASC respond to intravenous 
steroids and in those non-responsive to steroids therapeutic options are either surgical 
colectomy or second line rescue medical therapy (Cyclosporin, Tacrolimus, Infliximab). 
Historically rates of rescue medical therapy were low (26%) and colectomy rates high (30-
70%) (14,15) but this pattern is changing towards most children, in the absence of a surgical 
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abdomen or toxic megacolon, being offered medical rescue therapy (4,5) reducing the short 
term colectomy rates in ASC to 10-20% (15,16). 
A national IBD audit has been undertaken on 4 occasions in the UK. The first round did not 
include paediatric sites and was published in 2006. The subsequent audits - round 2 (2008), 
round 3 (2010) and round 4 (2013) have all included paediatric sites. UK IBD audit paediatric 
data from 2008 and 2010 have been compared in a previous publication (14) and showed 
improvements in some elements of inpatient care of children with UC, including centres 
delivering higher rates of rescue therapy in patients who did not respond to steroids.  However 
round 2 and 3 audits were of the total paediatric inflammatory bowel disease population and 
therefore had proportionally small numbers of children with UC.   
The fourth round of the UK IBD 2013 audit focussed exclusively on the inpatient care provided 
to young people admitted to children’s hospitals in the UK for treatment of UC, including those 
undergoing surgery. A report on this and previous audits was generated from the Royal College 
of Physicians to enable hospitals and paediatric services to implement action plans and changes 
and benchmark their centre against national standards (17).  
We aim to examine morbidity and escalation treatment for children with active UC, steroid 
sparing strategies, proportion of second line treatment and surgical outcome, highlighting 
geographical differences, areas of improving practice and areas for future development.  
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Materials and Methods: 
 
 
Following prospective identification and notification of 35 secondary and tertiary hospital sites 
with a defined IBD lead, via a secure web-based data collection tool, 32 sites in the UK (total 
UK population 64.1 million in 2013, Office for national Statistics) entered clinical data on up 
to 50 consecutive admissions of children between less than 3 and up to 18 years between 1 
January and 31 December 2013 (table 1). The vast majority of sites took part with 24/25 
specialist paediatric sites and 8/10 non-specialist sites giving an overall UK site participation 
rate of 32/35 (94%) (table 2). The primary reason for the admission had to be for the treatment 
of UC and each admission must have been longer than 24 hours, thus excluding patients 
admitted only for endoscopy. Newly diagnosed cases, established diagnoses as well as multiple 
admissions of the same patient could be included. There were no age restrictions but patients 
had to be admitted to a paediatric centre for inclusion in the paediatric audit. It was predicted 
that very few UK paediatric sites would reach 50 admissions for UC over the course of a year 
so this methodology would therefore theoretically encompass 100% of their inpatient UC case 
load.  A small number of questions also addressed the outpatient care provided to each patient 
prior to their admission to hospital. 
 
Disease extent was defined using the Paris Classification (18) (table 1). Disease activity was 
assessed using the PUCAI score which is a validated, non-invasive, multi-item measure of 
disease activity with established cut-off values for remission (10 points), mild (10–34 points), 
moderate (35–64 points), and severe disease (65–85 points) (2,3). All data analysis including 
statistical analysis was performed by statisticians (LJW, HE, AP). Data are present as n (%) for 
categorical data or median interquartile range [IQR]) for continuous data. Analysis was 
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conducted using either a chi-square test, Fisher’s exact test, or Mann–Whitney test as 
appropriate. P < 0.05 was taken to indicate statistical significance. All analysis was performed 
using Stata 11 (StataCorp LLC, College Station, Texas 77845-4512, USA).  
 
 
Ethical considerations: 
 
Ethical permission was not required as this was an audit of clinical practice and all data was 
anonymised. 
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Results: 
 
 
Demographics and disease localisation 
Demographics, disease location, ambulatory time and disease activity are summarised in table 
1. The proportion of children admitted in non-specialised paediatric sites was 9% (27/298) 
(table 2).  
 
Comparison to previous audits 
A comparison of this audit documenting improvements to the previous 2 national audit rounds 
is shown in table 3 highlighting significant increases in guideline use, PUCAI recording, 
Clostridium difficile (C. difficile) analysis, anti-TNFalpha use, and colectomy rate.  
 
Patient distribution 
The median number of children entered per site was 6 (IQR 3,9). There were 2 outliers with 
regard to number of children entered, Liverpool and Newcastle, entering 50 and 36, 
respectively. These 2 centres together entered 41% of all cases (see further below).  
Excluding multiple admissions of the same child, 25% (55/224) were first presentations of UC. 
Considering previous admissions (41%), 17% had been readmitted within 30 days. The 
majority (61%) of patients with established UC were felt to have active disease when seen in 
an outpatient appointment prior to the admission and were admitted from clinic (27%), had 
their treatment changed (19%), but 54% were neither admitted to hospital nor had their 
treatment changed at that time. Standard stool cultures were sent off in 69% (85/123) of 
children with diarrhoea, with 8% (7/85) reported as positive, and stool cultures sent off for C. 
difficile in 60% (74/123) were reported as positive in 3% (2/74) (table 3).  
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68% of the children admitted with UC had extensive disease (E3 and E4), and 49% of total 
admissions had more than 6 bloody or loose stools per day (table 1). PUCAI was documented 
or not considered applicable in n=184 (61%) and not recorded in the remaining 114 (38%). Of 
those in whom it was recorded (n=135) the median score on their first admission was 65 (IQR 
55,70). 
 
Quality improvement 
Based on agreed national IBD standards, the concept for service improvements was to 
implement local actions identified as problems in previous audits (7, 14). This is illustrated in 
table 3, indicating increase of clinical nurse specialists (who provide direct and continuous 
contact and advice), establishment of guidelines for ASC (to reduce treatment variability and 
adherence to evidence-based protocols), recording of PUCAI score (to reduce bias in 
assessment of disease activity and treatment), transitional care plans (to facilitate continuity of 
specialist care), and other (table 3) (7). It had been recognised in previous audits that GPs in 
the UK were unfamiliar in the management of children with IBD, therefore the high proportion 
of patients seen within 7 days reflects improvements in surveillance and efficacy of a more 
rapid specialist service response for children with UC.  
 
Medical treatment 
183/298 (61%) of admissions received steroid therapy, 138/183 (75%) intravenous and 45/183 
(25%) orally. The progression on treatment for all patients, excluding the elective surgical 
admissions, is detailed in Figure 1. Of those receiving intravenous steroid therapy 2/3 had 
methylprednisolone and 1/3 hydrocortisone. Excluding readmissions (n=74) and newly 
diagnosed cases (n=55), 45/169 children (26%) received steroids for greater than 3 months in 
the previous 12 months. Steroid sparing agents were tried in this group, (Figure 2), but in 24% 
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only 5-aminosalicylic acid (5-ASA) or no steroid sparing agents (11/45) had been used. Of the 
34 children who had received steroid sparing therapy it was stopped due to lack of effect (8/34) 
or intolerance (2/34). In the remainder (24/34) it was continued but the child still required 
admission for active disease. 
 
 
Iron deficiency anaemia 
Anaemia was a significant finding in the group of children admitted with active UC. The 
median haemoglobin (g/dl) at first admission was 10.9 (IQR 9.1, 12.45) with 215/224 (96%) 
being anaemic using age related reference values. 110/215 (51%) were not previously known 
to be anaemic but 105/215 (49%) had been shown to be anaemic previously of which just under 
half had been identified as being anaemic > 3months prior to admission (figure 3).  Though 
51% of those identified as being iron deficient prior to admission had received iron therapy, 
half parenterally and half enterally, in 49% their iron deficiency had not been treated. In those 
treated, both parental and enteral iron was assessed as being 100% effective by the child’s 
clinical team. 
 
 
Surgery 
For the first time in this audit, all medical and surgical admissions were captured for this IBD 
cohort over a year, and surgical data such as ileal pouch surgery were captured systematically 
to monitor both frequency (table 3) and outcome (tables 4+5).  
53 children had 58 operations during their admissions, 35 admitted electively for surgery and 
23 children non-electively.  All children had one surgical procedure except one child who had 
3 and another who had 4 different surgeries, respectively. The indications for surgery 
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performed are shown in Table 4 and the type of procedures in Table 5. Most of the children 
requiring surgery in both the elective and non-elective admission had a colectomy, 21/35 and 
19/23 respectively, (p=0.38). Comparison of the audits rounds illustrates an increasing number 
of patients receiving anti-TNFalpha for rescue and maintenance therapy, but a similar 
proportion of children with UC requiring colectomy (table 3).  
 
Pouch surgery continues to be uncommon in the paediatric population with only seven elective 
procedures recorded in this 1 year period. Laparoscopic or laparoscopically assisted surgery 
was used in 12/30 (40%) of all resecting procedures and there was no statistical difference in 
the use of laparoscopic techniques in the elective or non-elective surgical groups (p=0.49). 
Broad categories of surgical complications were recorded in the audit with 19/58 (35%) of all 
operations. Infections were prominent in emergency procedures (5/35) whereas stoma and 
motility problems in elective operations (6/23). Complications appear different per urgency of 
the procedure (Figure 4).  Intrabodominal sepsis and anastomotic leakage was described in 
4/55 (7%) children undergoing elective or non elective surgery. The proportion of children who 
had surgery for toxic megacolon was 2/55 (4%); the overall rate of toxic megacolon being 
2/224 patients admitted with UC (table 3).  
 
 
National consistency 
To analyse why 2/32 centres (Liverpool and Newcastle) had disproportionately large numbers 
of children admitted with UC, subanalysis of their data was undertaken. Newcastle and 
Liverpool jointly had 86 (median 43.5 (IQR 36, 50)) admissions during the study period 
compared to 212 in the other 30 sites (median 6 (IQR 3, 9)) (Mann-Whitney U test p=0.004); 
with the next largest centre entering 17 children. When compared to all other sites Newcastle 
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and Liverpool had a significantly larger overall IBD population, median 283.5 (IQR 252, 315) 
versus median 165 (IQR 84,264) (Mann-Whitney test, p=0.004) but the proportion of children 
with UC or IBD-U was no different in Liverpool and Newcastle (43%) to national figures 
(41%). PUCAI scores were more consistently recorded in Liverpool and Newcastle in 78%, 
(67, 86) versus 55% other sites (117, 212; p=0.004) and were similar on admission (median 
PUCAI 65 versus 65) and on discharge (median PUCAI 10 versus 15)(n.s.).  
The mode of admission (elective versus emergency) was higher electively in 
Liverpool/Newcastle (20/86, 23%) versus others (23/212, 11%)(p=0.004) and respectively 
Liverpool/Newcastle had a lower rate of emergency admissions (30/86, 35%) versus other 
centres (102/212, 48%) (p=0.037). A slightly higher rate of readmissions of children with UC 
in Liverpool/Newcastle in the previous two years (54/86, 63%) versus others (112/212, 53%) 
was statistically not significant (p=0.12), and if patients had to be admitted for surgery or had 
surgery performed their proportion was similar in Liverpool/Newcastle to  the other centres. 
Although not formally asked in the audit questionnaire, we further interviewed participating 
centres if there was a treatment difference regarding steroid application, steroid sparing, 2nd 
line therapy, or use of biologics. In their region, children requiring inpatient treatment for UC 
were always admitted in Liverpool and Newcastle, while it was practice in some other tertiary 
centres to arrange admission and treatment for less severe UC in secondary hospitals from their 
network. In acute severe colitis (PUCAI score 65-85) , the Liverpool centre administered i.v. 
steroids as high dose bolus (20mg/kg), but applied similar second line treatment and steroid 
reduction scheme as other units.  
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Discussion: 
Our national audit programme over six years was conducted to improve clinical standards in 
order to reduce morbidity of children with UC, implement steroid sparing strategies, optimise 
escalation treatment, assess surgical outcomes, identify and resolve geographical differences.  
 
 
Quality indicator rescue therapy in ASC 
Second-line therapy in the steroid failure group has changed over the audit rounds and now the 
majority of children requiring second-line therapy receive anti-TNFα rather than Cyclosporine; 
with clinicians more comfortable with its use as maintenance therapy due to national licence. 
All 13 children receiving Cyclosporine as second line therapy avoided colectomy, whereas 
three of the 16 (18.8%) receiving anti-TNFα required colectomy as failed to respond to anti-
TNFα therapy. This is comparable to a single centre experience from Italy (n= 32) for children 
with ASC, of which 20% treated with infliximab required urgent colectomy and further 50% 
required colectomy in a 2 year follow-up (19). According to a meta-analysis from 2011, 
Infliximab was considered as effective with a pooled 1-year response of 64% as cyclosporine 
(75% n = 126, six studies) (20). Our national paediatric audit data and the paediatric meta-
analysis are in contrast to data from the previous UK audit (203  sites, n=1836 admissions) on 
adults with ASC, in which second-line therapy response was more frequently observed with 
anti-TNFa  (80%) than with Cyclosporin (58%), indicating the necessity to conduct paediatric 
studies and the pitfalls of extrapolating adult data to paediatric conditions (21). Our data appear 
to contrast paediatric head to head RCTs which showed not difference between the two 
treatments, but it is a limitation of our data that it relates only to inpatient admissions and does 
not describe the long-term outcome of the overall cohort (20).  
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Quality indicator: steroid sparing in refractory UC 
Steroid dependency is a major problem in children with UC as in addition to the common 
side effects of long-term steroids it can affect their growth and pubertal development (5).  
 
Historically, using mainly 5-ASA and azathioprine/6-mercaptopurine , the North American 
IBD network reported steroid dependency as 45% (22). More recently, an USA-network 
reported steroid dependency from their whole cohort (including stable outpatients and 
inpatients) as 15%, based on optimised Azathioprine/6-mercaptopurine levels, special 
training and coaching of doctors and nurses, audit and self-report on performance (23), 
however the proportion of patients on anti-TNFalpha was not reported. We escalated 
treatment to thiopurines, infliximab, or cyclosporine in 76% of inpatients. To our knowledge 
there is no published data about children admitted for treatment of UC, but our rate of steroid 
dependency of 26% (45/170) over one year indicates substantial improvement to previous 
audits, and appears comparable to recent reports from USA (14,22,23). 
Notably, an alternative treatment for successful treatment of ASC published recently by the 
Liverpool centre, was applied in 5% (15/298) of children admitted in this audit (24). Based 
on a short-term course of high dose (20mg/kg) iv methylprednisolone, with this protocol the 
steroid dependency rate had been reported before as 21% after 6 months and 0% after 1 year 
(24).  
 
 
Quality indicator: iron treatment in iron deficiency anaemia:  
In our previous audit, iron deficiency anaemia had been recognised as a major shortfall of 
quality indicators. One of the audit action plans had been to recognise and treat iron 
deficiency orally or intravenously (14). In this audit 61% of patients seen in clinic prior to 
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admission had iron deficiency anaemia. This is the first confirmation that paediatric 
gastroenterologists in the UK prescribe intravenous iron for iron deficiency anaemia in 
paediatric IBD. In a single-centre study from the USA, 24 children with IBD scheduled for 
infliximab treatment were iron deficient, which was corrected by administering i.v.-iron in 
63% and anaemia corrected in 79% (25). Our cohort is the largest number of children with 
paediatric UC (n=55) reported to benefit (100% efficacy) from the use of i.v. treatment. To 
address the deficit in all children with IBD, the BSPGHAN IBD working group produced a 
diagnostic and therapeutic algorithm available online (26). 
 
 
Quality indicator: colectomy rate 
In our series, the colectomy rate for children admitted for UC electively or urgently was 15%. 
This compares to a North American study of children admitted for ASC with a colectomy rate 
of 9% by discharge and 19% at 1 year follow-up (15). In another study from Italy, children 
with non-response to steroids had a 50% colectomy rate over 2 years despite escalating 
treatment with infliximab (19).   
The rate of toxic megacolon appears to decline over 3 audit rounds from 6% to 3% (p=0.29). 
As a sign of quality control over our audit rounds, restorative proctocolectomy (ileal pouch 
surgery) is offered and increasingly registered (4% to 56%), allowing for the first time 
monitoring of surgical outcomes and a benchmark for individual centres.  
 
 
Quality indicator: surgical complications 
In our series, 1 in 4 children admitted with UC required surgical management, highlighting the 
requirement for provision for medical and psychosocial consequences of colectomy or stoma. 
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Our data indicate the complications of surgery in paediatric UC are significant at 33%. This 
rate is comparable to other  published series with 25-33% (27, 28). Notably, postoperative 
complications in the UK in this audit were substantially better for urgent colectomies with 52% 
versus 90% in the USA, which may be a combination of timing, experience, 
immunosuppression, or other hospital characteristics and pathways. Elective colectomy, which 
us reported to have a better outcome of morbidity and mortality than urgent colectomy, was 
performed in higher proportion in the UK with 44% versus 37% in the USA, which may reflect 
the combined quality efforts to monitor disease activity early and to implement guidelines for 
ASC in all participating paediatric hospitals.  
Surgical complications not only affect morbidity for the individual child but adversely affect 
length and cost of the admission (27-29), highlighting the importance of optimising medical 
care and interdisciplinary teamwork. 
 
 
Addressing geographical differences 
Over six years, we demonstrated an increase in the application of guidelines for acute severe 
colitis from 43% to 77%, similar to reports from our adult gastroenterologists from 47% to 
84% in the same time (30). 
As a measure to monitor outcome of ileal pouch surgery in children with UC, a registry was 
established and promoted, leading to an increase of patient data entry from 4% to 56%, and 
illustrating the surgical actions to analyse and improve patient outcomes. Although it did not 
reach statistical significance in all variables, the three rounds of our national audit indicated 
reduction of the incidence of toxic megacolon, in agreement with the national adult IBD audit 
(14, 30, 31).  
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Along with an increasing number of patients treated with anti-TNFalpha, fewer children 
required colectomy, although this did not reach statistical significance. For future studies, it 
would be valuable to examine how patients perceived the preparation and timing of colectomy 
with regard to their quality of life, impact on growth, puberty, and psychosocial development. 
 
In contrast to other published national reports, which were limited to tertiary centres (14, 32, 
33), our audit was truly representative for the national practice including 9% of patients with 
severe UC managed in non-specialised sites. We observed a wide range in the catchment 
area, size of the IBD population, and referral pattern within regional networks over the audit 
period. The audit illustrated variation in areas of service provision (e.g. risk assessment by a 
nutritional screen) or compliance to quality standards (e.g. prescription of bone protection), 
which enables each individual hospital to benchmark against the national median and IQR (7, 
17).  
Our audit and action plan programme compares to an initiative for quality improvement in 
Northern America, that showed that early identification of children with sub-optimally 
managed disease and, where appropriate, early treatment escalation, has improved outcome 
(15). Another group from the USA has shown that adherence to agreed management targets 
can improve the proportion of children in remission of UC from 61% to 72%.  The fact that 
only 19% of our patients with active disease had a change of treatment or were admitted in 
27% indicates room for improvement in our system and action plans (23). 
 
 
Conclusions:  
Over 6 years, progress has been made that nearly all centres providing secondary and tertiary 
gastroenterology contributed to the national audit rounds, applying agreed quality standards of 
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PUCAI score, guidelines for acute severe colitis, and ileal pouch surgery registration. Nearly 
all children admitted had iron deficiency anaemia and half of them were prescribed oral or 
intravenous iron therapy, both considered as effective. More than half of inpatients with UC 
required iv steroids and of those one third were not responding and requiring second line 
therapy or surgery.  
More than half children with rescue therapy received anti-TNFalpha, and nearly 20% of those 
failed to respond and required colectomy. Although prescription of rescue therapy (50%) and 
proportion of anti-TNFalpha (50% of those) had significantly increased, over a period of 6 
years the reduction of colectomy rate (15%) had not reached statistical significance. Subtotal 
colectomy was required in 13.7% of patients admitted, nearly half of them admitted non-
electively, and complications occurred in one third of surgical patients with UC.  
Our national audit programme has proven effective to reduce steroid side-effects and iron 
deficiency anaemia in children with UC. Although over 6 years in the era of biologics there 
was a trend of decreasing colectomy rates, nearly half of children requiring colectomy had to 
be operated non-electively, indicating the importance of early recognition, optimising 
treatment, and collaborative gastro-surgical assessment.  
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Figure legends: 
 
Figures 1-4:  
[No legends required, information is contained in Figure titles] 
 
Figure 1: 
Treatment and progress of all admissions, excluding elective surgical admissions. 
 
Figure 2: 
Steroid sparing management in 45 children who received steroids for > 3 months in 12 
month prior to admission. Fifty steroid sparing agents were tried in 34 children, but no 
steroid sparing agents or only 5-aminocylic acid (5-ASA) was used in 11 children. 
 
Figure 3: 
Length of time n=105 children known to be anaemic prior to admission.  
 
Figure 4: 
Surgical complications in 35 elective and 23 non-elective surgical procedures 
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Table 1: 
Patient demographics and characteristics 
 
  Median (IQR) 
% (numerical) 
Age Total n=224 children 14 (11, 15) years 
Age distribution < 3  0.9% (2/224) 
 < 6 years 3.6% (8/224) 
 6 -18 years 95.5% (214/224) 
Gender Female 50.4% (113/224) Male 49.6% (111/224) 
 
Paris classification Proctitis (E1) 3% (8/298) 
 Left sided (E2) 18% (54/298) 
 Extensive (E3) 17% (52/298) 
 Pan colitis (E4) 51% (151/298) 
 Unknown 11% (33/298) 
Medication of patients not 
admitted from clinic 
5-ASA 52% (53/103)  
 Steroids 52% (53/103) 
 Topical 52% (53/103) 
 Thiopurine 52% (53/103) 
Ambulatory disease 
management 
Days prior to admission 26 (7, 61) days 
Tables
Previous admissions  Admitted for UC in previous 
2 years 
41% (92/212)  
PUCAI  On admission 60 (50, 70) 
 On discharge 15 (7.5,  25) 
Length of stay  6 (3, 10) days 
Type of admission  Newly diagnosed severe UC 18% (55/298)  
 Emergency admissions for 
established UC 
44% (131/298) 
 Elective medical or surgical 
admissions for known UC 
27% (52/298) 
 Transfer from other sites 11% (36/298) 
Comorbidity None 82% (245/298) 
 Cardiovascular 0.3% (1/298) 
 Respiratory 4% (11/298) 
 Diabetes 1% (4/298) 
 IBD related liver disease 7% (20/298) 
 Active cancer 0.7% (2/298) 
 Other 6% (17/298) 
Admissions n=298 admissions 13 (11, 14) years) 
 
 
 
  
Table 2:  
National recruitment of children with UC admitted over 1 year 
 
Centre City Admissions  
Alder Hey Children’s Hospital Liverpool 16.8% (50/298) 
Great North Children’s 
Hospital 
Newcastle upon Tyne 12.1% (36/298) 
Chelsea and Westminster 
Hospital, Children’s Services 
London 5.7% (17/298) 
Birmingham Children’s 
Hospital 
Birmingham 5.4% (16/298) 
Royal Hospital for Children 
Glasgow 
Glasgow 5.4% (16/298) 
Royal London Children’s 
Hospital, Barts Health 
London 5.0% (15/298) 
Southampton Children’s 
Hospital 
Southampton 4.7% (14/298) 
Leicester Royal Infirmary 
Children’s Hospital 
Leicester 4.0% (12/298) 
Royal Bristol Hospital for Sick 
Children 
Bristol 3.7% (11/298) 
King’s College Hospital London 3.7% (11/298) 
Children’s Hospital, John 
Radcliffe 
Oxford 3.4% (10/298) 
Leeds General Infirmary Leeds 2.7% (8/298) 
University Hospitals of 
North Midlands 
Stoke 2.7% (8/298) 
Royal Hospital for Sick 
Children Edinburgh 
Edinburgh 2.0% (6/298) 
Nottingham Children’s 
Hospital 
Nottingham 2.0% (6/298) 
Royal Free Hospital London 2.0% (6/298)  
Queen Mary’s Hospital for 
Children 
St Epsom and Helier 2.0% (6/298) 
St George’s Hospital London 2.0% (6/298) 
Morriston Hospital Swansea 1.7% (5/298) 
Addenbrooke’s Hospital Cambridge 1.7% (5/298) 
Tunbridge Wells Hospital Maidstone 1.7% (5/298) 
Royal Aberdeen Children’s 
Hospital 
Aberdeen 1.3% (4/298) 
Royal Belfast Hospital for Sick 
Children 
Belfast 1.3% (4/298) 
Royal Devon and Exeter 
Hospital 
Exeter 1.3% (4/298) 
Great Ormond Street Hospital London 1.3% (4/298) 
Luton and Dunstable 
University Hospital 
Luton 1% (3/298) 
Sheffield Children’s Hospital Sheffield 1% (3/298) 
Noah’s Ark Children’s Hospital Cardiff 0.7% (2/298) 
Jenny Lind Children’s Hospital Norwich 0.7% (2/298) 
University Hospital of North 
Tees 
Hartlepool 0.03% (1/298) 
The Children’s Hospital 
Lewisham 
Lewisham 0.03% (1/298) 
Royal Manchester Children’s 
Hospital 
Manchester 0.03% (1/298) 
Queen’s Hospital Burton Burton 0% (0/298) 
 
 
There are 25 specialist paediatric gastroenterology centres in the UK, of these 24 (96%) 
participated. Specific centres admitting smaller numbers of paediatric patients with UC were 
also invited to participate; of the additional 10 sites invited, eight participated giving a total of 
32/35 (94%) of all sites. The median number of children entered per site was 6 (IQR 3,9). 
 
 
 
  
Table 3: 
 
Comparison of the paediatric data in 3 rounds of the national UK inflammatory bowel 
disease (IBD) audits 
 
Variables examined Round 2 
2008-10 
Round 3 
2010-12 
Round 4 
2012-14 
χ2 test, p-value 
Participating centres N=23 N=24 N=32 NA 
Clinical nurse specialist for IBD 61% (14/23) 83% (20/24) 81% (25/31) 0.14 
Guidelines for Acute Severe Colitis 43% (10/23) 63% (15/24) 77% (24/31) 0.04 
Recording of PUCAI score on Day 1 in emergency 
admissions 
Not asked 23% (24/104) 55% (77/139) <0.001 
Transitional care in place Not asked Not asked 90% (28/31) NA 
Relapsing patients seen within 7 days 87% (20/23) 91% (21/23) 94% (29/31) 0.71 
Database or registry for IBD patients 48% (11/23) 78% (18/23) 68% (21/31) 0.09 
Ileal pouch surgery entered on registry Not asked 4% (1/23) 56% (9/16) <0.001 
Stool samples sent for Clostridium difficile 35% (44/124) 45% (57/126) 60% (74/123) <0.001 
Prescribed rescue therapy 
     Proportion = Cyclosporin A 
     Proportion = anti-TNFalpha 
26% (10/38) 
   80% (8/10) 
   20% (2/10) 
52% (17/33) 
   70% (12/17) 
   18% (3/17) 
49% (30/61) 
   43% (13/30) 
   53% (16/30) 
0.04 
0.051 
0.03 
Presence of toxic megacolon 6% (3/50) 4% (2/45) 3% (3/86) 0.79 
Plans for maintenance anti-TNFalpha Not asked 5% (11/173) 14% (24/177) 0.02 
Colectomy rate in steroid failures  23.7% (9/38) 15.2% (5/33) 15% (9/61) 0.50 
 
 
χ2 test was applied to compare rounds 2,3 and 4, where available. If round 2 were not available, 
p-values illustrate the comparison between rounds 3 and 4. 
 
 
  
Table 4: 
Indication for surgery in 58 children admitted with UC 
 
 
 
Elective surgical 
admission 
(n=35) 
Non-elective surgical 
admission 
(n=23) 
χ2 test, * 
Fisher’s 
exact test, p-
value 
Failure of medical therapy 22 (62.9%) 17 (73.9%) 0.38* 
Toxic megacolon 0 2 0.15 
Bleeding 2 1 1.0 
Obstruction 2 2 1.0 
Perforation 0 1 0.40 
Abscess 0 1 0.40 
Closure of stoma 9 0 0.008 
Pouch 1 0 1.0 
Other 1 0 1.0 
 
 
Children were admitted electively or non-electively for surgery of ulcerative colitis in round 4 
of the national audit.  
 
  
Table 5: 
Surgical procedure performed on 58 children admitted with UC 
 
 
 
Elective surgical 
admission  
(n=35) 
Non-elective 
surgical admission 
(n=23) 
Fisher’s exact test,  
 
p-value 
Subtotal colectomy 21 (60.0%) 19 (82.6%) 0.09 
Proctocolectomy 1 (2.9%) 0 (0%) 1.0 
Ileoanal pouch with stoma 2 (5.7%) 0 (0%) 0.51 
Ileoanal pouch without stoma 5 (14.3%) 0 (0%) 0.15 
Formation of ileostomy 17 (48.9%) 11 (47.8%) 1.0 
Other 6 (17.1%) 4 (17.4%) 1.0 
 
 
Children were admitted electively or non-electively for surgery of ulcerative colitis in round 4 
of the national audit.  
 
 
 
 
 
FIGURES 
 
Figure 1: 
Treatment and progress of all admissions, excluding elective surgical admissions. 
 
 
  
Figures
Figure 2: 
Steroid sparing management in 45 children who received steroids for > 3 months in 12 
month prior to admission. Fifty steroid sparing agents were tried in 34 children, but no 
steroid sparing agents or only 5-aminocylic acid (5-ASA) was used in 11 children. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thiopurine, 
n =28
Other, 
n = 2
Methotrexate,
n = 7
Anti TNF, 
n = 10
Ciclosporine, 
n = 1
Mycophenolate n = 2
None/5ASA, 
n = 11
Figure 3: 
Length of time n=105 children known to be anaemic prior to admission.  
 
 
 
 
 
 
  
≤ 3 months, 
n =55
52%
≤ 6 months, 
n = 22
21%
≤ 12 months,
n = 10
10%
> 12 months,
n =18
17%
Figure 4: 
Surgical complications in 35 elective and 23 non-elective surgical procedures 
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